Akebia Therapeutics (AKBA) News Today $1.80 -0.11 (-5.50%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Sell" Rating by StockNews.comFebruary 19 at 2:30 AM | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Cut to Sell at StockNews.comStockNews.com lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.February 18 at 1:16 AM | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Drop in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 14,450,000 shares, a decline of 19.7% from the January 15th total of 17,990,000 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 6.4 days.February 15, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Raised to "Hold" at StockNews.comStockNews.com raised Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.February 10, 2025 | marketbeat.comAkebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues DeclineFebruary 10, 2025 | seekingalpha.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of StockFebruary 5, 2025 | insidertrades.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CAO Richard C. Malabre sold 30,202 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $63,424.20. Following the completion of the sale, the chief accounting officer now owns 280,248 shares of the company's stock, valued at approximately $588,520.80. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 4, 2025 | marketbeat.comSteven Keith Burke Sells 50,506 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) SVP Steven Keith Burke sold 50,506 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.10, for a total transaction of $106,062.60. Following the completion of the transaction, the senior vice president now directly owns 816,234 shares of the company's stock, valued at $1,714,091.40. This trade represents a 5.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 4, 2025 | marketbeat.comNicholas Grund Sells 55,621 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) insider Nicholas Grund sold 55,621 shares of Akebia Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $116,804.10. Following the transaction, the insider now directly owns 442,579 shares in the company, valued at approximately $929,415.90. The trade was a 11.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 4, 2025 | marketbeat.comInsider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO Sells 144,250 Shares of StockAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John P. Butler sold 144,250 shares of Akebia Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $302,925.00. Following the sale, the chief executive officer now directly owns 2,604,330 shares of the company's stock, valued at approximately $5,469,093. This trade represents a 5.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.February 4, 2025 | marketbeat.comAkebia Therapeutics' chief accounting officer sells $63,424 in stockFebruary 4, 2025 | msn.comAkebia Therapeutics' chief commercial officer sells $116,804 in stockFebruary 4, 2025 | msn.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest UpdateAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 16,680,000 shares, an increase of 18.6% from the December 31st total of 14,070,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is presently 7.9 days.January 31, 2025 | marketbeat.comH.C. Wainwright maintains Akebia stock Buy rating, $7.50 targetJanuary 24, 2025 | msn.comAkebia Therapeutics (NASDAQ:AKBA) Trading 10.9% Higher - Time to Buy?Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9% - Time to Buy?January 23, 2025 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Trading Down 4.4% - What's Next?Akebia Therapeutics (NASDAQ:AKBA) Stock Price Down 4.4% - Time to Sell?January 23, 2025 | marketbeat.comAkebia Therapeutics' (AKBA) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Thursday.January 23, 2025 | marketbeat.comAkebia price target raised to $10 from $5 at BTIGJanuary 22, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9% - Should You Buy?Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 10.9% - Here's What HappenedJanuary 21, 2025 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by Barclays PLCBarclays PLC increased its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 276.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 273,085 shares of the biopharmaceutical company's stock after purchasing an additiJanuary 20, 2025 | marketbeat.comFY2024 Earnings Estimate for AKBA Issued By HC WainwrightAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical companyJanuary 18, 2025 | marketbeat.comBrokers Set Expectations for AKBA FY2024 EarningsAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities researchers at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce expects that the biopharmaceutical compJanuary 17, 2025 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Increase in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 16,680,000 shares, a growth of 18.6% from the December 15th total of 14,070,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 7.9 days.January 17, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for AKBA FY2029 Earnings?Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical coJanuary 17, 2025 | marketbeat.comFY2029 Earnings Forecast for AKBA Issued By HC WainwrightAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - HC Wainwright issued their FY2029 earnings per share estimates for Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings peJanuary 16, 2025 | marketbeat.comStockNews.com Downgrades Akebia Therapeutics (NASDAQ:AKBA) to SellStockNews.com lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.January 15, 2025 | marketbeat.comAkebia Therapeutics: Strong Market Position and Growth Potential Justifies Buy RatingJanuary 14, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Tuesday.January 14, 2025 | marketbeat.comAkebia announces ‘multiple positive business updates’January 13, 2025 | markets.businessinsider.comAkebia Therapeutics Announces Multiple Positive Business UpdatesJanuary 13, 2025 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold RatingStockNews.com raised Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday.January 7, 2025 | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 2, 2025 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.comStockNews.com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday.December 30, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street CorpState Street Corp raised its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 24.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,430,527 shares of the biopharmaceutical cDecember 30, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Growth in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 14,070,000 shares, an increase of 21.7% from the November 30th total of 11,560,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is currently 7.1 days.December 29, 2024 | marketbeat.com404,718 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Acquired by Wellington Management Group LLPWellington Management Group LLP purchased a new stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 404,718 shares of the biopharmaceutical compaDecember 21, 2024 | marketbeat.comInvestors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five yearsDecember 21, 2024 | uk.finance.yahoo.comInvestors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five yearsDecember 21, 2024 | uk.finance.yahoo.comAkebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.December 13, 2024 | marketbeat.comAkebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trialDecember 3, 2024 | markets.businessinsider.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisDecember 3, 2024 | prnewswire.comAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 25, 2024 | prnewswire.comQ3 2024 Earnings: Hold Akebia TherapeuticsNovember 20, 2024 | seekingalpha.comPiper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)November 14, 2024 | markets.businessinsider.comVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseaseNovember 14, 2024 | prnewswire.comAkebia Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | prnewswire.comAkebia Therapeutics Prepares for Vafseo LaunchNovember 10, 2024 | markets.businessinsider.com Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Media Mentions By Week AKBA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.430.60▲Average Medical News Sentiment AKBA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼33▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NAMS News IDYA News SDGR News TVTX News BLTE News VERA News IOVA News PRAX News GLPG News WVE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
